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Abstract ADVANCE was a 2-year, double-blind, placebo-
controlled, Phase 3 study in 1512 patients aged 18–65 years
with relapsing-remitting multiple sclerosis, which demon-
strated that peginterferon beta-1a 125 mcg administered
subcutaneously every 2 or 4 weeks led to significant reduc-
tions in annualized relapse rate (ARR) compared with pla-
cebo. This analysis examined ARR over 2 years in
ADVANCE across subgroups. Patients were treated with
peginterferon beta-1a every 2 weeks or every 4 weeks, or
placebo during Year 1. Thereafter, patients on placebo were
re-randomized to peginterferon beta-1a every 2 weeks or
every 4 weeks (delayed treatment). Subgroup analyses were
conducted by demographics and baseline disease character-
istics. The following results compared ARR in these sub-
groups for patients in continuous 2-week treatment versus
continuous 4-week treatment. ARR was similar in most
demographic and baseline disease characteristic subgroups
evaluated within the peginterferon beta-1a every-2-week arm
or every-4-week arm over 2 years. Although for both doses
some differences in the point estimates for ARR were noted
among the subgroups, considerable overlap in the confidence
intervals suggested that the efficacy of peginterferon beta-1a
is similar in all patients irrespective of gender, age, body
weight, geographical region, and disease activity at initiation
of treatment. Within each peginterferon beta-1a dosing group,
ARR was generally similar across most subgroups.
Keywords Interferon  Pegylated  Peginterferon beta-1a 
Multiple sclerosis  Relapsing-remitting  Clinical trial 
Phase 3
Introduction
Peginterferon beta-1a is a new treatment for relapsing-
remitting multiple sclerosis (RRMS) with the advantage of
a more convenient, low frequency, subcutaneous (SC)
dosing regimen compared with other beta interferons [1, 2].
The ADVANCE study was a 2-year, multicenter, ran-
domized, double-blind, parallel-group trial, with a 1-year
placebo-controlled period, designed to evaluate the safety
and efficacy of SC peginterferon beta-1a 125 mcg admin-
istered once every 2 or 4 weeks in patients with RRMS
(ClinicalTrials.gov number NCT00906399).
Primary results and 2-year follow-up data for the whole
study population (N = 1512) have been published [3, 4].
At the end of the placebo-controlled period (Year 1), both
peginterferon beta-1a dosing regimens met the primary
endpoint [reduced annualized relapse rate (ARR)]. Pegin-
terferon beta-1a every 2 weeks resulted in a numerically
greater treatment effect across relapse activity outcomes
and magnetic resonance imaging (MRI) endpoints than
peginterferon beta-1a every 4 weeks [3]. ARR was further
reduced in Year 2 with every-2-week dosing, and main-
tained with every-4-week dosing [4].
& Scott D. Newsome
snewsom2@jhmi.edu
1 Department of Neurology, Johns Hopkins University,
Baltimore, MD, USA
2 Department of Neurology, Medical Faculty, Heinrich-Heine
University, Du¨sseldorf, Germany
3 Biogen, Cambridge, MA, USA
4 Montreal Neurological Institute, McGill University,
Montreal, QC, Canada
5 NeuroRx Research, Montreal, QC, Canada
6 Pathology 627, Johns Hopkins Neuroimmunology and
Neuroinfectious Diseases, Johns Hopkins Hospital, 600 N.
Wolfe St., Baltimore, MD 21287, USA
123
J Neurol (2016) 263:1778–1787
DOI 10.1007/s00415-016-8182-4
The safety profile of peginterferon beta-1a was similar
across both dosing regimens and placebo in the first year
[3], and adverse events (AEs) were consistent with those of
the established disease-modifying treatments for RRMS in
the interferon-beta class, with injection-site reactions (ISR)
and flu-like symptoms (FLS) being the most commonly
reported AEs [5–8]. The safety profile during the non-
placebo controlled second year of active treatment was
consistent with Year 1 in terms of incidence, severity, and
most common AE [3, 4].
To test whether the favorable efficacy reported in
ADVANCE is consistent across different types of patients
in the RRMS study population, we performed a pre-spec-
ified subgroup analysis of ARR at Year 1 which was
repeated using data over 2 years. Sensitivity analyses were
also conducted to assess the robustness of the primary
endpoint results.
Methods
Study design and patients
The study design and patient population of the ADVANCE
study have been described in detail previously [3]. In brief,
patients aged 18–65 years who had been diagnosed with
RRMS (McDonald criteria 1–4), had a baseline Expanded
Disability Status Scale (EDSS) score of B5.0, and had
experienced C2 relapses within the last 3 years (includ-
ing C1 relapse in the 12 months prior to randomization)
were included in the study. Patients were randomized 1:1:1
to receive self-administered SC treatment with placebo,
peginterferon beta-1a 125 mcg every 2 weeks, or pegin-
terferon beta-1a 125 mcg every 4 weeks. To maintain
blinding, all patients received an injection every 2 weeks;
patients in the peginterferon beta-1a every-4-weeks group
had alternating injections of peginterferon beta-1a 125 mcg
and placebo. At the end of Year 1, patients in the placebo
group were re-randomized to SC peginterferon beta-1a
every 2 weeks or every 4 weeks (delayed treatment).
Patients were excluded if they had progressive forms of
multiple sclerosis (MS) or had received prior interferon
beta treatment for RRMS exceeding 4 weeks or discon-
tinued interferon treatment within 6 months prior to
baseline.
The ADVANCE study protocol was approved by the
Institutional Review Board at each site and was performed
in accordance with the International Conference on Har-
monization Guidelines for Good Clinical Practice and the
Declaration of Helsinki. All patients provided written
informed consent before entering the study.
Outcome measures
The primary endpoint was ARR at Week 48, as reported
previously [3]. Relapses were defined as new or recurrent
neurologic symptoms not associated with fever or infec-
tion, lasting C24 h, and accompanied by new objective
neurologic findings upon evaluation by the examining
neurologist. Relapses were confirmed by an Independent
Neurology Evaluation Committee (INEC). Standardized
neurological assessments including EDSS were performed
at baseline, every 12 weeks, and at the time of suspected
relapse. MRI scans were performed at screening and at
Weeks 24, 48, and 96, and were assessed centrally by an
expert reader blinded to treatment allocation.
Statistical analyses
In the primary analysis, ARR (total number of relapses
divided by patient-years in the study, excluding data
obtained after patients switched to alternative multiple
sclerosis drugs) was analyzed for the intent-to-treat (ITT)
population with a negative binomial regression model
adjusted for baseline EDSS score (\4 vs C4), baseline
relapse rate (number of relapses in 3 years before study
entry divided by 3), and age (\40 vs C40 years). Subgroup
and sensitivity analyses were performed as follows.
Subgroup analyses
ARR was evaluated in pre-specified analyses at Year 1, and
repeated at 2 years, among subgroups based on baseline
demographics and disease characteristics. The baseline
demographics subgroups assessed included: gender, age (\40
and C40 years), weight (by quartiles), and geographical
regions [Region 1 (Western Europe and North America):
Belgium, France, Germany, The Netherlands, Spain, United
Kingdom, the United States, and Canada; Region 2 (Eastern
Europe): Bulgaria, Croatia, Czech Republic, Estonia, Greece,
Latvia, Poland, Romania, Russian Federation, Serbia, and
Ukraine; Region 3 (South and Central America, Asia, and
Australia): Chile, Colombia, Mexico, Peru, Georgia, India, and
New Zealand]. Regions were grouped based on similarities in
healthcare delivery system. Disease characteristic subgroups
examined included: relapses during the previous 3 years
(2,[2); McDonald criteria (1 vs 2, 3, 4); prior MS treatment
(‘‘Yes’’ vs ‘‘No’’); EDSS score (\4 vs C4); T2 hyperintense
lesion volume (above or below median); and presence of
gadolinium-enhancing (Gd?) lesions (present vs absent).
Year 1 subgroup analyses of ARR were performed in
ITT population, for peginterferon beta-1a every 2 weeks or
every 4 weeks compared with placebo. Beyond Year 1, no
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patients remained on placebo. Subgroup analyses of ARR
over 2 years were performed in the ITT population, and
results are presented for patients who had received con-
tinuous active treatment from baseline, with comparison
between peginterferon beta-1a every-2-weeks dosing and
every-4-weeks dosing.
Sensitivity analyses
Five sensitivity analyses were conducted for the primary
endpoint to compare ARR in peginterferon beta-1a every
2 weeks and every 4 weeks versus placebo groups at
Year 1. The analyses of ARR included: (1) the per-
protocol population; (2) the ITT population using a
Poisson regression model (whereas the primary analysis
used a negative binomial regression model); (3) the ITT
population including all relapses reported on the
unscheduled relapse assessment visit (whereas the pri-
mary analysis included INEC-confirmed relapses only);
(4) the ITT population based on protocol-defined
objective relapses; and (5) the ITT population using a
negative binomial regression model with presence/ab-
sence of baseline Gd? lesions as a covariate in the
model (as well as baseline EDSS, baseline relapse rate,
and age, which were the factors included in the model in
the primary analysis). Similar sensitivity analyses were
performed over 2 years for patients who had received
continuous active treatment from baseline, with com-
parison between every-2-weeks dosing and every-4-
weeks dosing.
Table 1 Baseline demographic, disease, and MRI characteristics
Placebo
(n = 500)
Peginterferon beta-1a 125 mcg
every 2 weeks (n = 512)
Peginterferon beta-1a
125 mcg every 4 weeks
(n = 500)
Age (years) 36.3 (9.7) 36.9 (9.8) 36.4 (9.9)
Women, n (%) 358 (72) 361 (71) 352 (70)
Weight (kg) 69.2 (16.2) 69.6 (17.4) 68.3 (14.6)
White ethnic origin, n (%) 412 (82) 416 (81) 409 (82)
Geographic region, n (%)
India 56 (11) 58 (11) 56 (11)
North America 17 (3) 19 (4) 16 (3)
Western Europe 38 (8) 41 (8) 39 (8)
Eastern Europe 354 (71) 355 (69) 355 (71)
Rest of the world 35 (7) 39 (8) 34 (7)
Time since first MS symptoms (years) 6.3 (6.3) 6.9 (6.6) 6.5 (6.1)
Time since MS diagnosis (years) 3.5 (4.6) 4.0 (5.1) 3.4 (4.4)
Relapses within the previous 3 years 2.6 (1.00) 2.6 (0.99) 2.5 (0.77)
Relapses within the previous 12 months 1.6 (0.67) 1.6 (0.67) 1.5 (0.62)
EDSS score 2.44 (1.18) 2.47 (1.26) 2.48 (1.24)
\4, n (%) 432 (86) 423 (83) 413 (83)
C4, n (%) 68 (14) 89 (17) 87 (17)
Patients without Gd? lesions, n (%) 296 (59) 334 (65) 297 (59)
Number of Gd? lesions 1.6 (3.8) 1.2 (3.4) 1.8 (5.4)
Number of T2 lesions 50.6 (35.7) 48.7 (36.8) 51.4 (36.0)
Volume of T2 lesions, cm3 10.1 (11.9) 9.8 (11.6) 11.3 (13.2)
Previous treatmenta, n (%)
Glatiramer acetate 24 (5) 27 (5) 28 (6)
Interferon beta-1b 6 (1) 8 (2) 5 (1)
Interferon beta-1a 5 (1) 4 (\1) 6 (1)
Other 58 (12) 56 (11) 58 (11)
Data are mean (SD) or n (%)
EDSS Expanded Disability Status Scale, Gd? gadolinium-enhancing, MRI magnetic resonance imaging, MS multiple sclerosis
a Patients who had taken more than one drug were counted more than once: the total number of patients who had previously been treated was
260 (17 %)
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Results
Baseline disposition and characteristics
A total of 1512 patients were randomized and received treat-
ment with placebo (n = 500), peginterferon beta-1a 125 mcg
every 2 weeks (n = 512) or peginterferon beta-1a 125 mcg
every 4 weeks (n = 500). The ITT population included all
patients who were randomized and received at least 1 active
dose of study treatment. This population was used for all
analyses in this manuscript, using available data until the time
of dropout for patients dropping out prior to the end of Year 2.
Fig. 1 Pre-specified a and post
hoc b sensitivity analyses for
ARR at Year 1
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As reported previously [3, 4], baseline demographics
and disease characteristics were well balanced across the
treatment groups (Table 1). Year 1 of the study was com-
pleted by 86, 88, and 91 % of patients receiving pegin-
terferon beta-1a every 2 weeks, peginterferon beta-1a
every 4 weeks, and placebo, respectively. Year 2 of the
study was completed by 89, 94, 88, and 86 % of patients in
continuous treatment every 4 weeks and every 2 weeks and
delayed treatment every 4 weeks and every 2 weeks,
respectively. Baseline characteristics did not differ
Fig. 2 Analysesa of adjusted
annualized rate of relapse by
baseline demographic
characteristics: a at Year 1
(peginterferon beta-1a every
2 weeks vs placebo i and
peginterferon beta-1a every
4 weeks vs placebo ii); b over
2 years (peginterferon beta-1a
every 2 weeks vs every
4 weeks)
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significantly across regions, and clinical behavior was
similar across different regions (data not shown).
Primary efficacy results
The ARR at Year 1 was 0.397 relapses per patient-year
(95 % CI 0.328–0.481) in the placebo group, 0.256
(0.206–0.318) in the every 2 weeks group, (36 % lower,
p = 0.0007) and 0.288 (0.234–0.355) in the every 4 weeks
group (28 % lower, p = 0.011, Fig. 1) [3]. Compared with
Year 1, ARR was further reduced in Year 2 with continued
every-2-week dosing (from 0.256 to 0.178) and maintained
with continued every-4-week dosing (0.288 vs 0.291) [4].
Subgroup analyses of ARR by baseline demographic
characteristics
ARR at Year 1 and over 2 years by baseline demographic
characteristics is shown in Fig. 2. At Year 1, significant
reduction in ARR was evident with peginterferon beta-1a
every 2 weeks compared with placebo, regardless of age
and gender. All of the subgroups stratified by weight or
grouped by geographical region showed numerical reduc-
tions in ARR with peginterferon beta-1a every 2 weeks
versus placebo, with some subgroups reaching significance
(Fig. 2a, i). Effects of peginteferon beta-1a every 4 weeks
showed similar trends to peginterferon beta-1a every
2 weeks across subgroups defined by demographic char-
acteristics at Year 1 (Fig. 2a, ii). In the over-2-years
analyses, the ARR achieved with peginterferon beta-1a
every 2 weeks was numerically lower than with peginter-
feron beta-1a every 4 weeks for most of the subgroups
analyzed (Fig. 2b).
Subgroup analyses of ARR by baseline disease
characteristics
ARR at Year 1 and over 2 years by baseline disease
characteristic subgroups is shown in Fig. 3. At Year 1,
peginterferon beta-1a every 2 weeks produced significant
reductions in ARR compared with placebo across most of
the subgroups evaluated according to baseline disease
characteristics (Fig. 3a, i). Peginterferon beta-1a every
4 weeks showed similar trends, with consistent numerical
reductions in ARR compared with placebo, although sig-
nificance was reached in fewer subgroups than with
peginterferon beta-1a every 2 weeks (Fig. 3a, ii). ARR
over 2 years was numerically lower in patients receiving
peginterferon beta-1a every 2 weeks versus every 4 weeks
across most baseline disease characteristics subgroups
evaluated, reaching significance in some of the largest
subgroups in which variation was smaller, such as treat-
ment-naı¨ve patients, those meeting McDonald criterion 1,
and those with baseline EDSS score\ 4 (Fig. 3b).
Fig. 2 continued
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Fig. 3 Analysesa of adjusted
annualized rate of relapse by
baseline disease characteristics:
a at Year 1 (peginterferon beta-
1a every 2 weeks vs placebo
i and peginterferon beta-1a
every 4 weeks vs placebo ii);
b over 2 years (peginterferon
beta-1a every 2 weeks vs every
4 weeks)
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Sensitivity analyses in the overall study population
Results from the sensitivity analyses at Year 1 were con-
sistent with the primary analysis as reported by Calabresi
et al. [3] (Fig. 1). Compared with placebo, ARR was sig-
nificantly reduced in the peginterferon beta-1a every-2-
weeks (34–38 %) and every-4-weeks (27–31 %) groups.
Sensitivity analyses over 2 years are shown in Fig. 4.
Fig. 3 continued
Fig. 4 Post-hoc sensitivity
analyses for ARR over 2 years
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Compared with peginterferon every 4 weeks, ARR was
significantly reduced (22–27 %) in the peginterferon beta-
1a every-2-weeks group.
Discussion
In the ADVANCE trial, subgroup analysis of the primary
endpoint, ARR, across clinically relevant subpopulations of
RRMS patients with varied baseline demographics and
disease characteristics, found that peginterferon beta-1a
treatment demonstrated generally consistent benefits in
terms of ARR, with results that were similar to those
observed in the primary analysis. These findings suggest
that, among the general RRMS population, most subgroups
of patients could derive benefit from treatment with
peginterferon beta-1a.
There was considerable overlap in the 95 % confidence
intervals (CI) for rate ratios for peginterferon beta-1a ver-
sus placebo in Year 1 across the examined subgroups
(although some point estimate differences across subgroups
were observed), indicating that peginterferon beta-1a had
similar efficacy for reduction in ARR regardless of gender,
age, weight, geographical region, and baseline disease
characteristics. While some subgroups failed to reach sta-
tistical significance for peginterferon beta-1a versus pla-
cebo (as indicated by 95 % CI for rate ratios crossing 1),
this tended to be in smaller subgroups which exhibited a
higher degree of variability, and so may be related to
reduced statistical power in small subgroups. For example,
stratification by weight produced 4 smaller subgroups,
which had wider 95 % CIs than larger subgroups in the
binary categories such as age and gender; among the
geographical regions, Region 2 (Eastern Europe) was the
largest subgroup and had the tightest 95 % CIs, revealing
significant effects of both peginterferon beta-1a every
2 weeks and every 4 weeks compared with placebo. Sim-
ilarly, over 2 years, there were some differences in ARR
among the subgroups, but the overlap in 95 % CIs sug-
gested that the treatment effect of peginterferon beta-1a
every 2 weeks on ARR was greater than with every-4-
weeks dosing in most subgroups defined by baseline
demographic characteristics. Among subgroups defined by
baseline disease characteristics, peginterferon beta-1a
treatment every 2 weeks over 2 years demonstrated gen-
erally consistent efficacy versus every 4 weeks on ARR
(the primary endpoint).
Sensitivity analyses, which examine the influence of
protocol design errors, unintended biases, and deviations
from assumptions of underlying models, are designed to
assess whether a primary endpoint result is robust and
generalizable. The current sensitivity analyses
demonstrated that the primary endpoint of the
ADVANCE study was robust across 2 years, with little
difference in outcomes across several pre-planned and
post hoc analyses.
Conclusion
Peginterferon beta-1a demonstrated generally consistent
benefits on the primary endpoint of ADVANCE, ARR at
Year 1, across clinically relevant subgroups of RRMS
patients with varied baseline demographic and disease
characteristics. Similar results were observed over 2 years.
Overall, these subgroup and sensitivity analyses support
the results from the primary analysis, indicating that
peginterferon beta-1a has the potential to provide benefits
to patients with MS, with a convenient, low-frequency, SC
dosing regimen.
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